Literature DB >> 34206654

Trial Design for a Diagnostic Accuracy Study of a Point-of-Care Test for the Detection of Taenia solium Taeniosis and (Neuro)Cysticercosis in Community Settings of Highly Endemic, Resource-Poor Areas in Zambia: Challenges and Rationale.

Inge Van Damme1, Chiara Trevisan1,2, Kabemba E Mwape3, Veronika Schmidt4,5, Pascal Magnussen6, Gideon Zulu3,7, Chishimba Mubanga1,3, Dominik Stelzle4, Emmanuel Bottieau8, Emmanuel Abatih9, Isaac K Phiri3, Maria V Johansen10, Chishala Chabala11,12, Andrea S Winkler4,5, Pierre Dorny2, Sarah Gabriël1.   

Abstract

Field-applicable, high-quality, and low-cost diagnostic tools are urgently needed for Taenia solium. The aim of this paper is to describe the design, challenges, and rationale for the design of a diagnostic accuracy study in low-resource community settings in Zambia. The trial was designed as a prospective study with a two-stage design to evaluate a new point-of-care test (TS POC) for the detection of taeniosis and (neuro)cysticercosis. Participants within randomly selected households were tested with the TS POC test (index test). Participants who tested TS POC positive for taeniosis and/or cysticercosis and a subset of the negatives were requested to give blood and stool samples for reference testing, and to undergo clinical examination and a cerebral CT scan. The difficulties of conducting a clinical trial in settings with limited research and neuroimaging infrastructure as well as peculiarities specifically related to the disease (low prevalence of taeniosis and the lack of a gold standard) were taken into consideration for the design of this study. The two-stage design increased the efficiency of the study by reducing the number of samples, clinical examinations, and CT scans. Simplified flows and sampling processes were preferred over complex follow-up and randomization systems, aiming to reduce bias and increase the generalizability of the study.

Entities:  

Keywords:  POC test; Taenia solium; accuracy; cysticercosis; diagnosis; low-resource settings; point-of-care; sensitivity; specificity; taeniosis

Year:  2021        PMID: 34206654     DOI: 10.3390/diagnostics11071138

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  26 in total

1.  An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium).

Authors:  V C Tsang; J A Brand; A E Boyer
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

Review 2.  Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity.

Authors:  N M Buderer
Journal:  Acad Emerg Med       Date:  1996-09       Impact factor: 3.451

Review 3.  Diagnostic Accuracy Studies.

Authors:  Michaël Chassé; Dean A Fergusson
Journal:  Semin Nucl Med       Date:  2018-12-13       Impact factor: 4.446

Review 4.  Revised diagnostic criteria for neurocysticercosis.

Authors:  O H Del Brutto; T E Nash; A C White; V Rajshekhar; P P Wilkins; G Singh; C M Vasquez; P Salgado; R H Gilman; H H Garcia
Journal:  J Neurol Sci       Date:  2016-11-21       Impact factor: 3.181

5.  Validation of meat inspection results for Taenia saginata cysticercosis by PCR-restriction fragment length polymorphism.

Authors:  Dirk Geysen; Kirezi Kanobana; Bjorn Victor; Richar Rodriguez-Hidalgo; Jean De Borchgrave; Jef Brandt; Pierre Dorny
Journal:  J Food Prot       Date:  2007-01       Impact factor: 2.077

6.  Characterization, cloning, and expression of two diagnostic antigens for Taenia solium tapeworm infection.

Authors:  Min Z Levine; J C Calderón; Patricia P Wilkins; William S Lane; John M Asara; Kathy Hancock; Armando E Gonzalez; Hector H Garcia; Robert H Gilman; Victor C W Tsang
Journal:  J Parasitol       Date:  2004-06       Impact factor: 1.276

Review 7.  Neurocysticercosis in sub-Saharan Africa: a review of prevalence, clinical characteristics, diagnosis, and management.

Authors:  Andrea Sylvia Winkler
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

8.  Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries.

Authors:  Nitika Pant Pai; Caroline Vadnais; Claudia Denkinger; Nora Engel; Madhukar Pai
Journal:  PLoS Med       Date:  2012-09-04       Impact factor: 11.069

9.  Diagnostic randomized controlled trials: the final frontier.

Authors:  Marc Rodger; Tim Ramsay; Dean Fergusson
Journal:  Trials       Date:  2012-08-16       Impact factor: 2.279

10.  The incidence of human cysticercosis in a rural community of Eastern Zambia.

Authors:  Kabemba E Mwape; Isaac K Phiri; Nicolas Praet; Niko Speybroeck; John B Muma; Pierre Dorny; Sarah Gabriël
Journal:  PLoS Negl Trop Dis       Date:  2013-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.